Phase 2 study to evaluate the clinical efficacy and safety of medi4736 (durvalumab [DUR]) in patients with glioblastoma (GBM): results for cohort b (DUR monotherapy), bevacizumab (BEV) naive patients with recurrent GBM Conference Paper uri icon

authors

  • Reardon, David
  • Kaley, Thomas
  • Dietrich, Jorg
  • Lim, Michael
  • Dunn, Gavin
  • Gan, Hui
  • Cloughesy, Timothy
  • Clarke, Jennifer
  • Park, Andrew
  • Macri, Mary
  • Ryan, Aileen
  • Ricciardi, Toni
  • Reddy, Vijay
  • Venhaus, Ralph

publication date

  • 2016